VIATRIS INC. Interest Expense
VIATRIS INC. (VTRS) reported Interest Expense of $120.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-06
- VIATRIS INC. interest expense for the quarter ending 2026-06-30 was $120.70M, a 3.52% increase year-over-year.
- VIATRIS INC. interest expense for the quarter ending 2026-03-31 was $120.10M, a 3.98% increase year-over-year.
- VIATRIS INC. interest expense for the quarter ending 2025-12-31 was $119.60M, a 0.50% decline year-over-year.
- VIATRIS INC. interest expense for the quarter ending 2025-09-30 was $119.60M, a 17.86% decline year-over-year.
- VIATRIS INC. interest expense for fiscal 2025 was $471.30M, a 14.31% decline from fiscal 2024.
- VIATRIS INC. interest expense for fiscal 2024 was $550.00M, a 4.03% decline from fiscal 2023.
- VIATRIS INC. interest expense for fiscal 2023 was $573.10M, a 3.26% decline from fiscal 2022.
- VIATRIS INC. interest expense for fiscal 2022 was $592.40M, a 6.88% decline from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $120.70M 10-Q · filed 2026-08-06 | $240.80M 10-Q · filed 2026-08-06 | $360.40M derived: sum of 3 quarters · filed 2026-08-06 | $480.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $120.10M 10-Q · filed 2026-05-07 | $239.70M derived: sum of 2 quarters · filed 2026-05-07 | $359.30M derived: sum of 3 quarters · filed 2026-05-07 | $475.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $119.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $239.20M derived: sum of 2 quarters · filed 2026-02-26 | $355.80M derived: sum of 3 quarters · filed 2026-08-06 | $471.30M 10-K · filed 2026-02-26 |
| 2025-09-30 | $119.60M 10-Q · filed 2025-11-06 | $236.20M derived: sum of 2 quarters · filed 2026-08-06 | $351.70M 10-Q · filed 2025-11-06 | $471.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $116.60M 10-Q · filed 2026-08-06 | $232.10M 10-Q · filed 2026-08-06 | $352.30M derived: sum of 3 quarters · filed 2026-08-06 | $497.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $115.50M 10-Q · filed 2026-05-07 | $235.70M derived: sum of 2 quarters · filed 2026-05-07 | $381.30M derived: sum of 3 quarters · filed 2026-05-07 | $527.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $120.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $265.80M derived: sum of 2 quarters · filed 2026-02-26 | $411.60M derived: sum of 3 quarters · filed 2026-02-26 | $550.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $145.60M 10-Q · filed 2025-11-06 | $291.40M derived: sum of 2 quarters · filed 2025-11-06 | $429.80M 10-Q · filed 2025-11-06 | $570.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $145.80M 10-Q · filed 2025-08-07 | $284.20M 10-Q · filed 2025-08-07 | $425.10M derived: sum of 3 quarters · filed 2026-02-26 | $566.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $138.40M 10-Q · filed 2025-05-08 | $279.30M derived: sum of 2 quarters · filed 2026-02-26 | $420.80M derived: sum of 3 quarters · filed 2026-02-26 | $564.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $140.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $282.40M derived: sum of 2 quarters · filed 2026-02-26 | $426.10M derived: sum of 3 quarters · filed 2026-02-26 | $573.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $141.50M 10-Q · filed 2024-11-07 | $285.20M derived: sum of 2 quarters · filed 2024-11-07 | $432.20M 10-Q · filed 2024-11-07 | $579.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $143.70M 10-Q · filed 2024-08-08 | $290.70M 10-Q · filed 2024-08-08 | $437.80M derived: sum of 3 quarters · filed 2025-02-27 | $591.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $147.00M 10-Q · filed 2024-05-09 | $294.10M derived: sum of 2 quarters · filed 2025-02-27 | $447.30M derived: sum of 3 quarters · filed 2025-02-27 | $593.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $147.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $300.30M derived: sum of 2 quarters · filed 2025-02-27 | $446.20M derived: sum of 3 quarters · filed 2025-02-27 | $592.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $153.20M 10-Q · filed 2023-11-08 | $299.10M derived: sum of 2 quarters · filed 2023-11-08 | $445.30M 10-Q · filed 2023-11-08 | $593.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $145.90M 10-Q · filed 2023-08-07 | $292.10M 10-Q · filed 2023-08-07 | $440.30M derived: sum of 3 quarters · filed 2024-02-28 | $592.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $146.20M 10-Q · filed 2023-05-08 | $294.40M derived: sum of 2 quarters · filed 2024-02-28 | $446.30M derived: sum of 3 quarters · filed 2024-02-28 | $613.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $148.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $300.10M derived: sum of 2 quarters · filed 2024-02-28 | $467.20M derived: sum of 3 quarters · filed 2024-02-28 | $636.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $151.90M 10-Q · filed 2022-11-07 | $319.00M derived: sum of 2 quarters · filed 2022-11-07 | $488.00M 10-Q · filed 2022-11-07 | $632.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $167.10M 10-Q · filed 2022-08-08 | $336.10M 10-Q · filed 2022-08-08 | $480.50M derived: sum of 3 quarters · filed 2023-02-27 | $597.80M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $169.00M 10-Q · filed 2022-05-09 | $313.40M derived: sum of 2 quarters · filed 2023-02-27 | $430.70M derived: sum of 3 quarters · filed 2023-02-27 | |
| 2020-12-31 | $144.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $261.70M derived: sum of 2 quarters · filed 2023-02-27 | $497.80M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $117.30M 10-Q · filed 2021-11-08 | $353.40M 10-Q · filed 2021-11-08 | ||
| 2020-09-27 | $71.00M 10-Q · filed 2020-11-10 | $187.20M derived: sum of 2 quarters · filed 2021-08-09 | $76.00M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $116.20M 10-Q · filed 2021-08-09 | $236.10M 10-Q · filed 2021-08-09 | ||
| 2020-06-28 | $5.30M 10-Q · filed 2020-08-12 | $5.30M 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | $119.90M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $517.30M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $542.30M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |